CD8A and myeloid sarcoma: However, in our study none of the DMF-treated MS patients showed a decline of CD4+ T cells below the lower limit of normal (LLN, 400/μl) and only 14% of the patients showed a decline of CD8+ T cells below the LLN (200/μl), which is in contrast with other studies24,25.